|
CNI Home |
Welcome pageWhat's NewCNI Center for Movement Disorders
|
| APPOINTMENTS
Our specialists are happy to discuss your individual case with you. Serious inquiries only, please. For an appointment, call 303-357-5455. |
The CNI Movement Disorders Center is actively involved in a broad spectrum of research projects from genetics to stereotactic surgery, new medications and testing methods. Some of the highlights are listed below. These are projects in addition to our state of the art evaluation and treatment services. If you are interested in specific projects or clinical trial opportunities, please e-mail NPyle@TheCNI.org, call us at 303-357-5455 or visit our CNI Research page.
Recover Trial—SP889
Rajeev Kumar, MD, Primary Investigator
Colorado Neurological Institute
701 E. Hampden Ave. Suite 510
Englewood, CO 80113
Diane Erickson, RN, CCRC, Coordinator
Phone # 303-764-6674
E-mail derickson@thecni.orgOverview: A phase IIIb trial looking at individuals diagnosed with Parkinson’s disease who have morning motor disturbances; the study is looking at effectiveness of medication called rotigotine (in a skin patch) on early morning mobility, sleep quality, nocturnal and non-motor symptoms. The study is double-blind, placebo-controlled, meaning besides previous medication, individuals receive either the rotigotine patch or a placebo patch.
Eligibility:
- Men and women age 18 years and older at the early and advanced stage of Parkinson’s disease with morning motor disturbances
- Stable doses of Parkinson’s drugs for 28 days before inclusion into study
- Attend the Colorado Neurological Institute research clinic up to 8 times within maximum of 22 weeks; at 2 visits, the subject will have to spend 2 nights in the Swedish Medical center sleep lab.
- Use the recommended contraceptive methods
- Additional criteria not listed here must be met.
Exercise Research Study for People with Parkinson's Disease
Margaret Schenkman, PT, PhD, Investigator
University of Colorado Denver
Recent evidence suggests that exercise may slow Parkinson’s disease.We invite you to help us learn more about exercise and Parkinson’s disease. Volunteers are needed for a research study at UCD to determine if exercise programs will improve daily function and help people with PD stay active.
We are looking for individuals who are:
Download a flyer about the study or, for more information or to see if you qualify to participate, please contact Pam Mettler at phone (303)724-1266 or e-mail PDstudy@uchsc.edu
- Able to function independently
- Have early to mid stages of PD
- Willing to be randomized to one of three groups:
- Home Exercise Program
- Aerobic Conditioning Program
- Flexibility and Function Program
2Care
Rajeev Kumar, MD, Primary Investigator
Diane Erickson, RN, CCRC, Coordinator
Colorado Neurological Institute
701 E. Hampden Ave. Suite 510
Englewood, Colorado 80113
Phone # 303-764-6674
E-mail derickson@thecni.orgOverview: 6.5 year, phase III study looking at the effects of coenzyme Q10 (CoQ-10) compared to placebo on the progression of functional decline in patients with Huntington disease. 5 clinic visits between screening and month 6, then clinic visits every 6 months; telephone contact between 6 month visits. Study drug will be supplied. Clinic visits will include assessment by Dr. Kumar and coordinator, movement ratings, lab draw, blood pressure and study drug dispensing.
Inclusion:
- Have clinical features of HD and confirmatory family history of HD
- Age 16 years and older
- Women of childbearing potential must not get pregnant during study.
- On stable doses of medications at time of enrollment
- Able to take medications by mouth
- No use of any CoQ-10 during the 4 months prior to enrollment
Predict-HD
Rajeev Kumar, MD, Primary Investigator
Diane Erickson, RN, CCRC, Coordinator
Colorado Neurological Institute
701 E. Hampden Ave. Suite 510
Englewood, CO 80113
Phone # 303-764-6674
E-mail derickson@thecni.orgOverview: A long-term, observational study looking at persons who have undergone Huntington disease genetic testing and are either gene positive or negative and are pre-symptomatic. Visits occur 1 time a year with telephone contact between visits. Visits include: movement assessment by Dr. Kumar, a blood draw, completion of self-assessments and assessments by companion, cognitive testing, MRI of brain at specific visits, review of medications and blood pressure.
Eligibility:
- 18 years and older
- Gene positive or negative for Huntington disease
- Able to have an MRI of the brain
- Certain medications not allowed
- Commitment of “companion” to attend visits and provide information
ccCOHORT – Cooperative Huntington’s Observational Research Trial
Rajeev Kumar, MD, Primary Investigator
Diane Erickson, RN, CCRC, Coordinator
Colorado Neurological Institute
701 E. Hampden Ave. Suite 510
Englewood, Colorado 80113
Phone # 303-764-6674
E-mail derickson@thecni.orgThis long-term observational study will initially take place at 45 North American and Australian Huntington Study Group (HSG) sites. The goal of COHORT is to collect information in order to learn more about HD, potential treatments, and to plan future research studies of experimental drugs aimed at postponing the onset or slowing the progression of HD. This study will recruit both adults and children who have clinically diagnosed HD and adults who are a part of an HD family. Individuals who choose to participate will have one study visit every year for as long as they are able and choose to participate.
At each annual visit, all individuals participating in COHORT will be required to have a clinical evaluation. Those who are 18 years of age and older will have blood drawn for genetic testing of the CAG polymorphism and for other genetic changes, which may be important to Huntington’s disease. For those who are 18 years of age and older, there will be optional research procedures including the collection of family history and the collection and storage of blood and urine for future HD research.
Data from the COHORT study will be collected in databases designed to protect the privacy of all those who participate. The data and samples will provide researchers with a valuable resource to address a wide variety of research questions in Huntington’s disease.
Clinical Evaluation
Each year COHORT participants will undergo a medical and neurological evaluation. This evaluation will include standardized assessments of movement, thinking, memory, ability to perform daily activities, and behavior. Also, a medical and neurological examination will be conducted and the participant will provide information about medical history and current medications.Collection of Blood for Genetic Testing
At the initial visit, all COHORT participants who are 18 years of age and older will have blood drawn for genetic testing of the CAG polymorphism and for other genetic changes, which may be important to Huntington’s disease. Since this testing will be experimental, neither the COHORT participants nor the site investigators will receive the results of this testing.Collection of Family History Information (optional)
Family history data will be used to learn more about the natural history of the disease over several generations. This information may uncover new details about why there are differences in how HD affects different families and different members within a family. Any COHORT participant 18 years of age and older with a family history of HD will be asked to participate. This part of the COHORT study is optional. If the participant chooses not to provide family history information, he or she may still take part in the COHORT study.The participant will be asked to complete a Family History Questionnaire (FHQ), which asks questions about the participant’s extended family, including:
- Family members’ names, birthdates, sex, and, if applicable, date of death
- For any affected family members, age of HD diagnosis and whether a physician made the diagnosis will be collected.
Collection and Storage of Biological Samples for Future HD Research (optional)
Scientists have found that blood, urine, and other biological samples contain clues about HD that may be used to better understand the progression of the disease and to develop new therapies. Any COHORT participant 18 years of age and older will be given the option of having blood and urine collected and stored for future HD research. If a participant chooses not to participate, he or she may still take part in the COHORT study. These samples will be labeled with a unique identification code and stored in a research facility.These stored samples will provide researchers with the resources necessary to study Huntington’s disease. Huntington’s disease researchers from institutions all over the world will be able to request samples for research in HD. All samples will be identified with a code, and researchers will not receive any personally identifying information about COHORT participants.
 |
| |
Colorado Neurological
Institute's Center for Movement Disorders
Directions & Parking
|
What's New at CNI
|
Site Map
|
Contact Us
|
Privacy Policy
|
|
